Pulmosonix brings forward clinical trials
12 November, 2002 by Melissa TrudingerMelbourne devices company Pulmosonix is planning to start clinical trials for its two medical devices earlier than originally foreshadowed, according to a recent announcement by parent company Premier Bionics.
GM poppies for the apple isle
11 November, 2002 by Melissa TrudingerGenetically modified oilseed poppies will be field-tested in Tasmania after receiving approval last week from both the Office of the Gene Technology Regulator (OGTR) and the Tasmanian State Government's Department of Primary Industries, Water and the Environment (DIPWE).
Shunning GM could cost future market share: report
11 November, 2002 by Graeme O'NeillA new economic model indicates Australia won't reap an export bonanza by adopting genetically modified (GM) crops, but could see its market share stagnate or decline if it rejects or over-regulates GM crops and foods.
Khan drops Biota takeover bid
08 November, 2002 by Pete YoungPerth entrepreneur Farooq Khan has junked his plan to pursue a scrip-based hostile takeover of Biota Holdings Ltd.
Ellex hit by sales slump, MD resignation
08 November, 2002 by Melissa TrudingerOphthalmic laser manufacturer Ellex Medical was battered this week after announcing a downturn in revenues caused by lower than expected sales, as well as the unanticipated resignation of managing director Peter Rowland due to differences with the board over the direction of the company.
Devine, Progen split
06 November, 2002 by Pete YoungQueensland biotech Progen Industries and business development vice president Dr Peter Devine have parted company.
Abbott-Domantis agreement may affect Peptech's future
06 November, 2002 by Graeme O'NeillPharmaceutical giant Abbott Laboratories has signed an agreement with UK-based Domantis that gives it non-exclusive access to Domantis' single-domain designer technology for new 'lite' antibody therapeutics.
Bioprocessing feature: Out of the vat
06 November, 2002 by Melissa TrudingerBioprocessing and fermentation are essential parts of the biotechnology product development cycle. If a drug or therapeutic is produced by a living organism, whether it's bacteria, yeast, plant cells or mammalian cells, some form of large-scale fermentation or culture is required to produce the entity, and usually some form of downstream processing is necessary to extract, purify, concentrate and formulate the end product.
VRI receives TGA approval
04 November, 2002 by Melissa TrudingerWestern Australian probiotics company VRI BioMedical has received Therapeutic Goods Administration (TGA) approval for its gastrointestinal product, Progastrim.
Ventracor to sell off its former core division
04 November, 2002 by Melissa TrudingerVentracor is in negotiations to sell off its e-Health division to a potential purchaser identified after a worldwide search.
GSK research award goes to epilepsy pioneer
01 November, 2002 by Melissa TrudingerAustralian epilepsy researcher Prof Sam Berkovic has been awarded the 2002 GlaxoSmithKline (GSK) Australia Award for Research Excellence for his pioneering discoveries of the genetic causes of epilepsy.
Cerylid, Peter Mac collaborate on anti-cancer drugs
31 October, 2002 by Melissa TrudingerCerylid and the Peter MacCallum Cancer Institute have set up a collaboration to look for new anti-cancer drug leads, using Cerylid's natural products library as a source.
Peptech down as European royalties cease
30 October, 2002 by Melissa TrudingerPeptech's share price plunged more than 50 per cent today after announcing that it had ceased receiving European royalties from US-based Centocor.
Meditech on course for Phase II after capital raising
29 October, 2002 by Graeme O'NeillMelbourne biotech company Meditech Research has launched a $3.5 million capital raising, underwritten by Intersuisse, to fund initial Phase II clinical trials of its HyACT anti-cancer treatments.
Starpharma subsidiary awarded $3.5 million by US govt
29 October, 2002 by Melissa TrudingerDendritic Nanotechnologies (DNT), a subsidiary of Melbourne organisation Starpharma, has received $US3.5 million ($6.3 million) from the United States government to establish facilities for applied dendrimer research and development at Central Michigan University (CMU).
